GlaxoSmithKline is to build a new manufacturing facility in the UK, as part of £500 million of investment which will create up to 1,000 jobs.
Glaxo’s proposed biopharmaceutical facility at Ulverston in Cumbria, is Glaxo’s first new manufacturing facility to be built in almost 40 years.
The commitment to the UK, including two manufacturing sites at Montrose and Irvine, follows confirmation in the Budget that the Government will introduce a "patent box" to encourage investment in research and development in the UK.
Glaxo, which employs 15,000 people in the UK with almost 6,000 in manufacturing, said construction on the £350 million project at Ulverston is expected to begin in 2014/15, dependent on planning consents. As well as Ulverston, existing Glaxo sites at Barnard Castle in County Durham and at Irvine and Montrose were assessed as locations for the facility.
The company may double investment on the Ulverston site to £700 million if there is a further improvement in the "environment for innovation". There are currently 240 Glaxo staff at Ulverston involved in the manufacturing of key ingredients for antibiotics.
Chief executive Sir Andrew Witty said the patent box, which introduces a lower rate of corporation tax on profits generated from UK-owned intellectual property, transformed the company's view of the UK as an investment location. He said it ensured that the "medicines of the future will not only be discovered, but also continue to be made here in Britain".
The additional £100 million of funding at the company's two sites in Scotland includes the production at Montrose of the key materials for Glaxo's portfolio of respiratory medicines. It will also be the first of Glaxo's UK sites to participate in the company's vaccine manufacturing supply chain.
At Irvine, Glaxo will increase production capacity for antibiotics as it looks to keep pace with growing demand in emerging markets.
There will be £80 million invested at its sites in Ware in Hertfordshire, to increase manufacturing capacity for its next-generation respiratory inhalation device, and at Barnard Castle, to establish a dermatology manufacturing centre of excellence.
Sir Andrew added: "We are also actively considering other investments in our UK manufacturing network which would create further jobs and reinforce the UK's international competitiveness and as a world leader in life sciences."
Chancellor George Osborne welcomed the announcement, citing it as proof the Government was improving the country's economy.
"You have GlaxoSmithKline, one of the world's biggest companies, one of the great British success stories, saying the Budget has changed their view of Britain as a place to invest," he told BBC Breakfast.
"They're going to create a thousand jobs here. Now, surely my responsibility as the country's Chancellor is to get the economy moving, to get jobs created, and when big companies say that about Britain, people should sit up and notice that we are changing the British economy for the better."